A Randomized, Double-Blind, Multi-Centre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in Combination with Weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2-Positive Metastatic Breast Cancer (Phase 1/3)

Trial Profile

A Randomized, Double-Blind, Multi-Centre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in Combination with Weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2-Positive Metastatic Breast Cancer (Phase 1/3)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Paclitaxel (Primary) ; Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Dr Reddys Laboratories
  • Most Recent Events

    • 01 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top